scholarly journals Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study

2015 ◽  
pp. 1581 ◽  
Author(s):  
Xiaodong Xie ◽  
Fand Guo ◽  
TAO HAN ◽  
Zhaozhe Liu ◽  
Xishuang Song ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Chinese Patients ◽  
Prognostic Analysis ◽  
Long Term Follow Up

Long-term follow-up in patients with metastatic renal cell cancer not treated with IL-2

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 4597-4597
Author(s):  
V. K. Chand ◽  
J. Sidloski ◽  
G. Clamon ◽  
R. J. Hohl
Keyword(s):  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Metastatic Renal Cell Cancer ◽  
Long Term Follow Up

scholarly journals Recurrent renal cell cancer: 10 years or more after nephrectomy

2013 ◽  
Vol 4 (2) ◽  
pp. 45 ◽  
Author(s):  
Emmanuel Abara ◽  
Iolanda Chivulescu ◽  
Nilam Clerk ◽  
Pablo Cano ◽  
Alexis Goth
Keyword(s):  
Renal Cell ◽  
Cell Cancer ◽  
Therapeutic Agents ◽  
Health Care Practitioners ◽  
Canadian Health ◽  
Long Term Follow Up ◽  
Canadian Health Care ◽  
Localized Renal Cell Carcinoma

Localized renal cell carcinoma (RCC) responds well to surgery.Patients often question how long they have to be on surveillanceafter their surgery. Several follow-up patterns have been describedin the literature. Until 2009, no published established Canadianguidelines existed to assist Canadian health-care practitioners inthe surveillance of these patients. We present 3 cases of RCC thatrecurred 10 years or longer after the initial nephrectomy. Thesecases emphasize the need for careful long-term follow-up, as recommendedin the Canadian Urological Association guidelines.We also discuss the optimism of prolonged disease survival inthe era of novel therapeutic agents that target angiogenesis.

Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group.

1994 ◽  
Vol 12 (4) ◽  
pp. 701-706 ◽  
Author(s):  
S Williams ◽  
J A Blessing ◽  
S Y Liao ◽  
H Ball ◽  
P Hanjani
Keyword(s):  
Germ Cell ◽  
Gynecologic Oncology ◽  
Cell Cancer ◽  
Germ Cell Tumors ◽  
Germ Cell Cancer ◽  
Gynecologic Oncology Group ◽  
Long Term Follow Up ◽  
Acute Myelomonocytic Leukemia

PURPOSE This study was performed to determine the effectiveness of postoperative adjuvant chemotherapy in patients with surgically resected ovarian germ cell tumors. PATIENTS AND METHODS After tumor removal and thorough surgical staging, patients were enrolled on this study and treated with three courses of cisplatin, etoposide, and bleomycin (BEP). Reassessment laparotomy was required of consenting, appropriate patients initially, but became an optional procedure in 1989. RESULTS Of 93 patients assessable on this trial, 89 are continuously free of germ cell cancer. At second-look laparotomy, two other patients were found to have small foci of immature teratoma; both remain clinically free of recurrence. One received subsequent alternate chemotherapy and one did not. Thus, 91 of 93 patients are currently free of germ cell cancer. Follow-up duration ranges from 4.0 to 90.3 months, with 67 patients monitored for longer than 2 years. Acute toxicity was moderate. One patient developed acute myelomonocytic leukemia 22 months after diagnosis. Another patient was noted to have a malignant lymphoma 69 months after protocol treatment. CONCLUSION Three courses of BEP will nearly always prevent recurrence in well-staged patients with completely resected ovarian germ cell tumors and should be given to all such patients. The development of acute leukemia as a complication of treatment is disturbing and mandates careful long-term follow-up, but is unusual and does not alter the risk-to-benefit ratio of treatment.

Sign in / Sign up

Export Citation Format

Share Document